Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 4,135.00
-15.00 (-0.36%)
Jan 21, 2026, 3:30 PM JST
Kaken Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | 1,597 | 19,435 | 9,796 | 6,817 | 13,885 | 18,657 | Upgrade |
Depreciation & Amortization | 2,720 | 2,554 | 2,753 | 2,568 | 2,486 | 2,318 | Upgrade |
Loss (Gain) From Sale of Assets | 1,578 | 1,555 | 167 | 1,911 | 2,896 | -333 | Upgrade |
Loss (Gain) From Sale of Investments | -1,119 | 287 | -13 | -1 | -1 | -115 | Upgrade |
Other Operating Activities | -7,655 | -842 | -3,788 | -4,407 | -4,431 | -5,517 | Upgrade |
Change in Accounts Receivable | 269 | 3,577 | -4,559 | 972 | 392 | 1,251 | Upgrade |
Change in Inventory | -549 | -1,084 | -1,603 | -583 | 241 | -2,923 | Upgrade |
Change in Accounts Payable | -230 | 1,100 | 880 | 280 | -2,630 | -112 | Upgrade |
Change in Other Net Operating Assets | 1,173 | 3,198 | -1,056 | 1,696 | 498 | 1,154 | Upgrade |
Operating Cash Flow | -2,216 | 29,780 | 2,577 | 9,253 | 13,336 | 14,380 | Upgrade |
Operating Cash Flow Growth | - | 1055.61% | -72.15% | -30.62% | -7.26% | -47.65% | Upgrade |
Capital Expenditures | -3,040 | -4,138 | -1,861 | -1,987 | -2,986 | -1,973 | Upgrade |
Sale of Property, Plant & Equipment | - | - | 1 | 12 | 704 | 874 | Upgrade |
Cash Acquisitions | -15,378 | -15,378 | - | - | -4,975 | - | Upgrade |
Sale (Purchase) of Intangibles | -538 | -254 | -306 | -219 | -271 | -313 | Upgrade |
Investment in Securities | 2,113 | 120 | 516 | -195 | 5 | 124 | Upgrade |
Other Investing Activities | 54 | - | -4,204 | -238 | -365 | -356 | Upgrade |
Investing Cash Flow | -16,789 | -19,650 | -5,854 | -2,627 | -7,888 | -1,644 | Upgrade |
Issuance of Common Stock | 7,764 | 7,764 | - | - | - | - | Upgrade |
Repurchase of Common Stock | -8,278 | -5,935 | - | -1,340 | -2,414 | -2,940 | Upgrade |
Common Dividends Paid | -7,240 | -7,198 | -5,657 | -5,649 | -5,714 | -5,811 | Upgrade |
Other Financing Activities | -1 | - | -1 | -1 | -1 | -1 | Upgrade |
Financing Cash Flow | -7,755 | -5,369 | -5,658 | -6,990 | -8,129 | -8,752 | Upgrade |
Miscellaneous Cash Flow Adjustments | -1 | -1 | - | - | 1 | -1 | Upgrade |
Net Cash Flow | -26,881 | 4,760 | -8,935 | -364 | -2,680 | 3,983 | Upgrade |
Free Cash Flow | -5,256 | 25,642 | 716 | 7,266 | 10,350 | 12,407 | Upgrade |
Free Cash Flow Growth | - | 3481.28% | -90.15% | -29.80% | -16.58% | -50.98% | Upgrade |
Free Cash Flow Margin | -6.41% | 27.27% | 0.99% | 9.96% | 13.61% | 16.55% | Upgrade |
Free Cash Flow Per Share | -137.58 | 671.92 | 18.97 | 193.39 | 272.53 | 321.51 | Upgrade |
Cash Interest Paid | 37 | 28 | 17 | 17 | 17 | 17 | Upgrade |
Cash Income Tax Paid | 7,649 | 836 | 3,788 | 4,409 | 4,431 | 5,516 | Upgrade |
Levered Free Cash Flow | -4,054 | 22,980 | -1,299 | 7,486 | 8,025 | 9,418 | Upgrade |
Unlevered Free Cash Flow | -4,031 | 22,998 | -1,289 | 7,497 | 8,036 | 9,429 | Upgrade |
Change in Working Capital | 663 | 6,791 | -6,338 | 2,365 | -1,499 | -630 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.